BrainStorm Cell Therapeutics Inc. Announces Final Analysis Of Phase...

The study achieved its primary endpoint in demonstrating that NurOwn is safe and well-tolerated at doses up to 2 million cells per kilogram administered intrathecally and 48 million cells administered intramuscularly . Importantly, nearly all subjects in this study experienced clinical benefit from treatment with NurOwn.

http://ift.tt/1BACLO0